Cerenome, Inc. (CNSY) income statement
CNSYNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 8/3067% below fair value
$0.70−0.00 (-0.62%)
Close on Nov 19, 2026Market cap $5.33MP/E –Yield –
Cerenome, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- –
- Operating margin
- -628.1%
- Net margin
- -620.7%
- Return on equity, FY2025
- 903.9%
Financial strength
- Current ratio
- 1.37
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 27.6%
Valuation
- P/E ratio
- –
- Price to sales
- 1.27
- Price to book
- 0.98
- Dividend yield
- –
See a number that looks wrong?